Parkman Healthcare Partners LLC holds a diversified book of 89 stocks worth $964.6M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Eli Lilly & Co and trimmed Boston Scientific Corp. Their largest long position is Stryker Corp at 5% of the equity book. They also disclosed $5.1M in put options (a bearish bet), shown separately below and excluded from the equity book.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
98% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Parkman Healthcare Partners LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 80 / 80 | $171.1B |
| MORGAN STANLEY | 80 / 80 | $35.2B |
| UBS Group AG | 80 / 80 | $12.3B |
| BANK OF AMERICA CORP /DE/ | 79 / 80 | $24.0B |
| GOLDMAN SACHS GROUP INC | 79 / 80 | $17.4B |
| BARCLAYS PLC | 79 / 80 | $5.0B |
| CITIGROUP INC | 79 / 80 | $2.7B |
| OSAIC HOLDINGS, INC. | 79 / 80 | $684.5M |
Ranked by how many of Parkman Healthcare Partners LLC's top 80 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Stryker Corporation COM | $50.9M | 154.8K | 5.3% | ▲+47% Added · +49K sh | |
| 2 | Dexcom Inc COM | $43.3M | 689.8K | 4.5% | ▲+17% Added · +102K sh | |
| 3 | Kalvista Pharmaceuticals Inc COM | $36.9M | 1.84M | 3.8% | ▲+3.8% Added · +67K sh | |
| 4 | Insulet Corp COM | $32.9M | 156.6K | 3.4% | ▲+11% Added · +16K sh | |
| 5 | Eli Lilly & Co COM | $31.8M | 34.6K | 3.3% | ▲New New position | |
| 6 | PTC Therapeutics Inc COM | $29.4M | 431.4K | 3.0% | ▲+169% Added · +271K sh | |
| 7 | Xenon Pharmaceuticals Inc COM | $28.9M | 497.0K | 3.0% | ▲+222% Added · +343K sh | |
| 8 | Boston Scientific Corp COM | $28.2M | 448.8K | 2.9% | ▼−10% Reduced · −52K sh | |
| 9 | CVS Health Corp COM | $27.8M | 387.3K | 2.9% | ▼−14% Reduced · −63K sh | |
| 10 | Arcus Biosciences Inc COM | $26.1M | 1.21M | 2.7% | ▲+25% Added · +239K sh | |
| 11 | Livanova PLC SHS | $25.7M | 404.0K | 2.7% | ▼−1.7% Reduced · −7K sh | |
| 12 | Zimmer Biomet Holdings Inc COM | $24.4M | 269.6K | 2.5% | ▲+78% Added · +119K sh | |
| 13 | MBX Biosciences Inc COM | $23.9M | 800.0K | 2.5% | ▼−9.7% Reduced · −86K sh | |
| 14 | Ani Pharmaceuticals Inc COM | $21.6M | 280.6K | 2.2% | ▲+94% Added · +136K sh | |
| 15 | Syndax Pharmaceuticals Inc COM | $21.1M | 901.5K | 2.2% | ▲+57% Added · +327K sh | |
| 16 | Qiagen NV ORD SHARES | $20.0M | 500.0K | 2.1% | ▲New New position | |
| 17 | Envista Holdings Corporation COM | $18.1M | 711.7K | 1.9% | ▲New New position | |
| 18 | Eyepoint Inc COM NEW | $17.5M | 1.35M | 1.8% | ▲+25% Added · +267K sh | |
| 19 | Abbvie Inc COM | $16.3M | 75.0K | 1.7% | ▲New New position | |
| 20 | Biocryst Pharmaceuticals Inc COM | $16.3M | 1.71M | 1.7% | ▲+90% Added · +808K sh | |
| 21 | Iqvia Hldgs Inc COM | $14.8M | 86.7K | 1.5% | ▲+146% Added · +51K sh | |
| 22 | Agios Pharmaceuticals Inc COM | $13.7M | 403.5K | 1.4% | ▲+305% Added · +304K sh | |
| 23 | Illumina Inc COM | $13.6M | 110.4K | 1.4% | ▲New New position | |
| 24 | Edwards Lifesciences Corp COM | $13.4M | 167.2K | 1.4% | ▲+11% Added · +16K sh | |
| 25 | Neurocrine Biosciences Inc COM | $13.1M | 99.1K | 1.4% | ▼−14% Reduced · −16K sh | |
| 26 | Kiniksa Pharmaceuticals Intl ORD SHS CL A | $12.5M | 259.2K | 1.3% | ▼−61% Reduced · −406K sh | |
| 27 | Assembly Biosciences Inc COM NEW | $11.4M | 411.2K | 1.2% | ▲+65% Added · +162K sh | |
| 28 | Structure Therapeutics Inc SPONSORED ADS | $11.2M | 232.1K | 1.2% | ▲+322% Added · +177K sh | |
| 29 | McKesson Corp COM | $11.0M | 12.7K | 1.1% | ▼−65% Reduced · −24K sh | |
| 30 | Stoke Therapeutics Inc COM | $11.0M | 336.5K | 1.1% | ▼−22% Reduced · −94K sh | |
| 31 | Viridian Therapeutics Inc COM | $10.9M | 557.9K | 1.1% | ▼−29% Reduced · −230K sh | |
| 32 | Waystar Hldg Corp COM | $10.7M | 443.1K | 1.1% | ▲+20% Added · +74K sh | |
| 33 | Mineralys Therapeutics Inc COM | $10.3M | 380.1K | 1.1% | ▼−7.3% Reduced · −30K sh | |
| 34 | Edgewise Therapeutics Inc COM | $10.2M | 322.8K | 1.1% | ▼−25% Reduced · −105K sh | |
| 35 | Xeris Biopharma Holdings Inc COM | $10.0M | 1.72M | 1.0% | ▲+1.8% Added · +30K sh | |
| 36 | Tenet Healthcare Corp COM NEW | $9.5M | 50.1K | 1.0% | ▼−17% Reduced · −10K sh | |
| 37 | Artivion Inc COM | $9.2M | 252.0K | 1.0% | ▲+15% Added · +33K sh | |
| 38 | Nuvalent Inc COM | $9.0M | 88.1K | 0.9% | ▼−26% Reduced · −31K sh | |
| 39 | Alphatec Hldgs Inc COM NEW | $9.0M | 823.8K | 0.9% | ▲+197% Added · +547K sh | |
| 40 | Alnylam Pharmaceuticals Inc COM | $8.9M | 26.9K | 0.9% | ▼−44% Reduced · −21K sh | |
| 41 | Axogen Inc COM | $8.9M | 268.2K | 0.9% | ▲+7.1% Added · +18K sh | |
| 42 | Immunome Inc COM | $8.8M | 403.5K | 0.9% | ▲+45% Added · +126K sh | |
| 43 | Amylyx Pharmaceuticals Inc COM | $8.6M | 621.5K | 0.9% | ▲+63% Added · +240K sh | |
| 44 | Idexx Labs Inc COM | $8.4M | 15.0K | 0.9% | ▲New New position | |
| 45 | Waters Corp COM | $7.9M | 26.4K | 0.8% | ▼−37% Reduced · −15K sh | |
| 46 | Adaptive Biotechnologies Cor COM | $7.7M | 551.8K | 0.8% | ▲+37% Added · +150K sh | |
| 47 | Upstream Bio Inc COM | $7.1M | 786.8K | 0.7% | ▼−5.7% Reduced · −48K sh | |
| 48 | Erasca Inc COM | $6.6M | 406.7K | 0.7% | ▲New New position | |
| 49 | Apogee Therapeutics Inc COM | $6.5M | 77.7K | 0.7% | ▼−40% Reduced · −52K sh | |
| 50 | Cooper Cos Inc COM | $6.4M | 89.9K | 0.7% | ▼−28% Reduced · −35K sh |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1777015/holdings"
Use Arkolith to show Parkman Healthcare Partners LLC's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | MODERNA INC | $5.1M | 100K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.